WayPath Pharma is a development-stage companion animal pharmaceutical company founded in 2019 by two Louisiana State University oncology researchers. With over 50 years of combined experience, the company focuses on developing new and innovative anti-cancer metabolic compounds for companion animals. WayPath holds the exclusive license and commercialization rights from LSU for over 300 variants of their lead compound, PP1. Their groundbreaking work aims to combat cancer in pets, addressing the significant need for effective treatments in the companion animal pharmaceutical industry.